Join the DDA or

Medley Pharma ranitidine recall

Further ranitidine recalled

December 17th 2019

Tagged: MHRA alert

By MHRA

Medley Pharma Limited is recalling all unexpired stock of  ranitidine 150mg and 300mg tablets BP as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

This is an on-going issue and follows several other ranitidine recall notices. Dispensers should return all remaining stock to their supplier. Patients taking ranitidine are advised to speak to the GP for medication review.

For stock control enquiries please contact Customer Service team on 01515214527 or sales@medleypharma.co.uk

For medical information enquiries please contact Jo Bunyan Pharmacovigilance Department on 07946548344 or jo@callisto-consulting.co.uk

 

For all the latest news of the 2020 DDA annual conference...

Learn more